Kipsbiopharma (hereafter referred to as Kipspharma) is accelerating its external growth by acquiring a lucrative pharmaceutical distribution company. The company plans to leverage its newly secured general hospital distribution infrastructure to actively target the oncology market, using it as a group-level growth lever.
On March 3, Kipspharma announced that it will acquire a 92% stake in Elpispharm, a comprehensive cancer drug distribution company, through its subsidiary KPT (KPT), which specializes in prescription drug distribution. As a result, Elpispharm will become a second-tier subsidiary of Kipspharma.
Elpispharm is a major pharmaceutical distributor in the central region, with numerous top-tier general hospitals-including university hospitals in the Chungcheong area-as its main clients. The company has maintained annual sales of around 30 billion won over the past three years and has consistently posted operating profits, making it a solid business.
Kipspharma plans to actively expand its business by utilizing Elpispharm's accumulated sales expertise and distribution know-how in cancer drugs. The acquisition paves the way for Kipspharma’s existing portfolio of over 200 prescription drug products to be distributed through general hospital channels, laying the foundation for mid- to long-term growth. Additionally, by internalizing distribution margins previously paid to external wholesalers, the group's profitability is expected to improve significantly.
In particular, synergy effects are anticipated for subsidiary BigThink Therapeutics, which has a diverse portfolio of cancer drugs, as it secures access to hospital distribution infrastructure with high entry barriers. The company plans to leverage Elpispharm’s delivery references and bidding expertise to quickly introduce BigThink’s cancer drug product line into major university hospitals.
A Kipspharma representative stated, "General hospital distribution requires a thorough understanding of each hospital’s business practices and complex margin structures, making it difficult to build expertise in a short period. The greatest achievement of this investment is that the acquisition of Elpispharm completes the end-to-end value chain from drug development and manufacturing to distribution."
KPT, the acquiring entity, aims to expand its existing pharmaceutical distribution business by utilizing Elpispharm’s hospital network and operational experience. The company seeks to go beyond simple wholesaling, strengthen its presence in the bidding market, and become a regionally based pharmaceutical distribution hub focused on the central region.
Kim Hayong, CEO of Kipspharma, stated, "The acquisition of Elpispharm is a strategic decision to strengthen our pharmaceutical and biotech business portfolio and secure a stable revenue base. We will achieve sustainable growth through organic cooperation among affiliates."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
